Famitinib is a tyrosine kinase receptor inhibitor developed by Jiangsu Hengrui for a variety of cancers. In China, in May 2025 famitinib was conditionally approved for use in combination with camrelizumab for the treatment of recurrent or metastatic cervical cancer in patients who have failed prior platinum-based chemotherapy and have not received prior bevacizumab.
Chemical compound
Famitinib
All data from the card 12
- Legal status
- Investigational
- CAS Number
- 1044040-56-3
- PubChem CID
- 16662431
- IUPHAR/BPS
- 7886
- DrugBank
- DB11741
- ChemSpider
- 17595500
- UNII
- 768FW21J3L
- ChEMBL
- ChEMBL1278146
- CompTox Dashboard (EPA)
- DTXSID301358976
- Formula
- C23H27FN4O2
- Molar mass
- 410.493 g·mol−1
- 3D model (JSmol)
- Interactive image
Read next
Justice Bao (2010 TV series)Chinese television series
The Legend and the Hero2007 Chinese television series
List of members of the Chinese Academy of Sciences
The Rebirth of a KingChinese television series
Romance of the Three Kingdoms (TV series)1994 Chinese television series
List of members of the Chinese Academy of Engineering
Romance of the Three Kingdoms (TV series)1994 Chinese television series
List of members of the Chinese Academy of EngineeringText from Wikipedia, CC BY-SA 4.0 · Source article